{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:44:50Z","timestamp":1794667490886,"version":"4.9.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-62056-7","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:39:42Z","timestamp":1753353582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-5653","authenticated-orcid":false,"given":"Aziz","family":"Zaanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Didelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-3364","authenticated-orcid":false,"given":"Chlo\u00e9","family":"Broudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-8258","authenticated-orcid":false,"given":"George","family":"Laliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-3559","authenticated-orcid":false,"given":"Erik","family":"Spickard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punashi","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Saltel-Fulero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-0638","authenticated-orcid":false,"given":"Francesco Giulio","family":"Sullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Pizzamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Widad","family":"Lahlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-3053","authenticated-orcid":false,"given":"Adham","family":"Jurdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-5232","authenticated-orcid":false,"given":"Minetta C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-5459","authenticated-orcid":false,"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"62056_CR1","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3390\/cancers15051628","volume":"15","author":"S Mantziari","year":"2023","unstructured":"Mantziari, S. et al. A comprehensive review of prognostic factors in patients with gastric adenocarcinoma. Cancers 15, 1628 (2023).","journal-title":"Cancers"},{"key":"62056_CR2","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393, 1948\u20131957 (2019).","journal-title":"Lancet"},{"key":"62056_CR3","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro, J. et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 16, 1090\u20131098 (2015).","journal-title":"Lancet Oncol."},{"key":"62056_CR4","doi-asserted-by":"publisher","unstructured":"Hoeppner, J. B. T. et al. Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA1 (2024).","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1"},{"key":"62056_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264912","volume":"14","author":"Y Lin","year":"2023","unstructured":"Lin, Y., Liang, H. W., Liu, Y. & Pan, X. B. Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial. Front. Immunol. 14, 1264912 (2023).","journal-title":"Front. Immunol."},{"key":"62056_CR6","doi-asserted-by":"publisher","first-page":"S1315","DOI":"10.1016\/j.annonc.2023.10.074","volume":"34","author":"YY Janjigian","year":"2023","unstructured":"Janjigian, Y. Y. et al. Pathological complete response (pCR) to durvalumab plus 5f luorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): interim results of the global, phase III MATTERHORN study. ESMO Ann. Oncol. 34, S1315\u2013S1316 (2023).","journal-title":"ESMO Ann. Oncol."},{"key":"62056_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen, S. et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial. J. Clin. Oncol. 42, 410\u2013420 (2024).","journal-title":"J. Clin. Oncol."},{"key":"62056_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani, D. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. 29, 127\u2013134 (2023).","journal-title":"Nat. Med."},{"key":"62056_CR9","first-page":"PO.21.00101","volume":"5","author":"F Loupakis","year":"2021","unstructured":"Loupakis, F. et al. Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases. JCO Precis. Oncol. 5, PO.21.00101 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"62056_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432\u2013437 (2021).","journal-title":"Nature"},{"key":"62056_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert, T. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5, 1124\u20131131 (2019).","journal-title":"JAMA Oncol."},{"key":"62056_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00420","volume":"6","author":"BM Huffman","year":"2022","unstructured":"Huffman, B. M. et al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis. Oncol. 6, e2200420 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"62056_CR13","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1053\/j.gastro.2021.07.011","volume":"161","author":"E Ococks","year":"2021","unstructured":"Ococks, E. et al. Serial circulating tumor DNA detection using a personalized, tumor-informed assay in esophageal adenocarcinoma patients following resection. Gastroenterology 161, 1705\u20131708.e2 (2021).","journal-title":"Gastroenterology"},{"key":"62056_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41591-023-02758-x","volume":"30","author":"YL Verschoor","year":"2024","unstructured":"Verschoor, Y. L. et al. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial. Nat. Med. 30, 519\u2013530 (2024).","journal-title":"Nat. Med."},{"key":"62056_CR15","doi-asserted-by":"crossref","unstructured":"Gerlinger M. G. A. & Barber L. J. Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma. Medicine (Baltimore). 102, e36228 (2023).","DOI":"10.1158\/1538-7445.AM2023-5591"},{"key":"62056_CR16","doi-asserted-by":"publisher","unstructured":"Takei S. K. D. & Sato K. Longitudinal circulating tumor DNA monitoring in patients with esophageal squamous cell carcinoma. JCO. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3041 (2023)","DOI":"10.1200\/JCO.2023.41.16_suppl.3041"},{"key":"62056_CR17","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran, S. E. et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 3, 1237\u20131244 (2017).","journal-title":"JAMA Oncol."},{"key":"62056_CR18","first-page":"109","volume":"37","author":"TE Kroese","year":"2022","unstructured":"Kroese, T. E. et al. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: a nationwide population-based cohort study. Clin. Transl. Radiat. Oncol. 37, 109\u2013115 (2022).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"62056_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000475550","volume":"93","author":"D Mizrak Kaya","year":"2017","unstructured":"Mizrak Kaya, D. et al. 101 long-term survivors who had metastatic gastroesophageal cancer and received local consolidative therapy. Oncology 93, 243\u2013248 (2017).","journal-title":"Oncology"},{"key":"62056_CR20","unstructured":"ClinicalTrials. Bethesda (MD): National Library of Medicine (US). Identifier NCT05965479 DcGATfGCD-c. https:\/\/clinicaltrials.gov\/ (2025)."},{"key":"62056_CR21","unstructured":"ClinicalTrials. Bethesda (MD): National Library of Medicine (US). Identifier NCT06253650 ATDfH-pGCWPomRD. https:\/\/clinicaltrials.gov\/ (2025)."},{"key":"62056_CR22","first-page":"2680","volume":"73","author":"AM Mandard","year":"1994","unstructured":"Mandard, A. M. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathol. Correlations. Cancer 73, 2680\u20132686 (1994).","journal-title":"Clinicopathol. Correlations. Cancer"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62056-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62056-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62056-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:34:18Z","timestamp":1757280858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62056-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62056"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62056-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have disclosed relevant conflicts of interest. G.L., E.S., P.D., M.M., S.S., H.S., A.J., and M.C.L. are employees of Natera, Inc. and have stock\/option to hold stock in the company. Additional COIs for M.C.L.: Grants\/Contracts: Funding to Institution (Mayo) from: Eisai, Exact Sciences, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics, Tesaro; Travel Support Reimbursement from AstraZeneca, Genomic Health, Ionis; Ad hoc advisory board meetings. All funds to Mayo Clinic. No personal compensation from AstraZeneca, Celgene, Roche\/Genentech, Genomic Health, GRAIL, Ionis, Merck, Pfizer, Seattle Genetics, Syndax. A.Z. has participated in consulting and\/or advisory boards for Amgen, Astellas, Merck, Roche, Servier, MSD, BMS, Pierre Fabre, Daiichi Sankyo, Astra Zeneca, Bayer, BeiGene, Astra Zeneca, Gilead, Abbvie. P.L.P. is the founder and shareholder of MethysDx, and a member of advisory board of Biocartis, Amgen, BMS, Pierre Fabre.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6815"}}